Windtree Therapeutics (WINT) Competitors $1.00 +0.01 (+1.01%) Closing price 04:00 PM EasternExtended Trading$1.03 +0.03 (+3.40%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock WINT vs. KZIA, CSCI, CVM, GOVX, MBIO, CYCN, PHXM, ARTL, SNSE, and LSBShould you be buying Windtree Therapeutics stock or one of its competitors? The main competitors of Windtree Therapeutics include Novogen (KZIA), COSCIENS Biopharma (CSCI), CEL-SCI (CVM), GeoVax Labs (GOVX), Mustang Bio (MBIO), Cyclerion Therapeutics (CYCN), PHAXIAM Therapeutics (PHXM), Artelo Biosciences (ARTL), Sensei Biotherapeutics (SNSE), and LakeShore Biopharma (LSB). These companies are all part of the "pharmaceutical products" industry. Windtree Therapeutics vs. Its Competitors Novogen COSCIENS Biopharma CEL-SCI GeoVax Labs Mustang Bio Cyclerion Therapeutics PHAXIAM Therapeutics Artelo Biosciences Sensei Biotherapeutics LakeShore Biopharma Novogen (NASDAQ:KZIA) and Windtree Therapeutics (NASDAQ:WINT) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, institutional ownership, earnings, profitability, risk, analyst recommendations and dividends. Do insiders and institutionals believe in KZIA or WINT? 30.9% of Novogen shares are owned by institutional investors. Comparatively, 29.3% of Windtree Therapeutics shares are owned by institutional investors. 1.0% of Novogen shares are owned by insiders. Comparatively, 0.3% of Windtree Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Does the media prefer KZIA or WINT? In the previous week, Windtree Therapeutics had 4 more articles in the media than Novogen. MarketBeat recorded 5 mentions for Windtree Therapeutics and 1 mentions for Novogen. Novogen's average media sentiment score of 0.66 beat Windtree Therapeutics' score of 0.54 indicating that Novogen is being referred to more favorably in the media. Company Overall Sentiment Novogen Positive Windtree Therapeutics Positive Is KZIA or WINT more profitable? Novogen's return on equity of 0.00% beat Windtree Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets NovogenN/A N/A N/A Windtree Therapeutics N/A -227.93%-56.46% Which has better valuation & earnings, KZIA or WINT? Windtree Therapeutics has lower revenue, but higher earnings than Novogen. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNovogen$1.51M6.60-$17.56MN/AN/AWindtree TherapeuticsN/AN/A-$1.79M-$823.470.00 Which has more volatility & risk, KZIA or WINT? Novogen has a beta of 2.64, indicating that its stock price is 164% more volatile than the S&P 500. Comparatively, Windtree Therapeutics has a beta of 0.7, indicating that its stock price is 30% less volatile than the S&P 500. Do analysts recommend KZIA or WINT? Novogen presently has a consensus price target of $14.00, indicating a potential upside of 41.99%. Windtree Therapeutics has a consensus price target of $350.00, indicating a potential upside of 34,900.00%. Given Windtree Therapeutics' higher possible upside, analysts clearly believe Windtree Therapeutics is more favorable than Novogen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Novogen 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50Windtree Therapeutics 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 SummaryNovogen beats Windtree Therapeutics on 10 of the 13 factors compared between the two stocks. Get Windtree Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for WINT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding WINT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart WINT vs. The Competition Export to ExcelMetricWindtree TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.62M$2.93B$5.49B$9.45BDividend YieldN/A2.49%4.01%4.03%P/E Ratio0.0020.5328.3319.89Price / SalesN/A267.80409.3186.88Price / CashN/A41.6635.9658.29Price / Book0.037.808.325.67Net Income-$1.79M-$55.10M$3.24B$258.18M7 Day Performance20.69%6.40%4.20%3.92%1 Month Performance75.44%16.84%10.16%14.31%1 Year Performance-99.44%3.12%34.69%17.29% Windtree Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)WINTWindtree Therapeutics2.9886 of 5 stars$1.00+1.0%$350.00+34,900.0%-99.5%$3.62MN/A0.0030Gap UpHigh Trading VolumeKZIANovogen3.7489 of 5 stars$11.43+5.8%$14.00+22.5%-65.8%$11.54M$1.51M0.0012CSCICOSCIENS BiopharmaN/A$3.62+2.5%N/AN/A$11.39M$9.03M-0.6220Positive NewsGap DownCVMCEL-SCI0.1631 of 5 stars$3.63+2.8%N/A-89.0%$11.01MN/A-7.5643High Trading VolumeGOVXGeoVax Labs2.0129 of 5 stars$0.69+1.4%$11.10+1,520.2%-70.7%$10.91M$3.95M-0.1910Analyst DowngradeGap UpMBIOMustang Bio0.7433 of 5 stars$2.42-8.7%N/A-87.1%$10.60MN/A-0.03100Gap DownCYCNCyclerion Therapeutics1.3369 of 5 stars$3.30-9.3%N/A+1.8%$10.59M$2M-2.8430Gap UpPHXMPHAXIAM TherapeuticsN/A$3.10flatN/AN/A$10.58MN/A0.0049ARTLArtelo Biosciences2.1443 of 5 stars$18.55-22.3%$25.00+34.8%+67.2%$10.20MN/A-1.035Gap DownSNSESensei Biotherapeutics4.3818 of 5 stars$8.08-1.1%$90.00+1,013.9%-42.4%$10.19MN/A-0.3540Positive NewsLSBLakeShore Biopharma0.3599 of 5 stars$1.11+2.8%N/A-78.0%$10.05M$80.82M0.00773 Related Companies and Tools Related Companies KZIA Competitors CSCI Competitors CVM Competitors GOVX Competitors MBIO Competitors CYCN Competitors PHXM Competitors ARTL Competitors SNSE Competitors LSB Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:WINT) was last updated on 7/22/2025 by MarketBeat.com Staff From Our PartnersTrump’s $100 Trillion Land Rush Is OnWhat Is "The US: IPO"? You won't hear this on CNBC... but the government may soon open up hundreds of trill...Stansberry Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredBitcoin just humbled Jeff BezosBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredSteve Jobs' Deathbed Secret Finally LeakedLeaked: Jobs’ Final Apple Project Exposed Bloomberg just leaked details of a secret project Steve Jobs set ...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Windtree Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Windtree Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
